Autologous T cells genetically engineered to express chimeric antigen receptors for MHC-independent recognition of lymphoma antigens (e.g., CD19/CD20/CD22), leading to potent T-cell activation and cytolytic killing.
Autologous T cells are genetically engineered to express chimeric antigen receptors that recognize lymphoma antigens (e.g., CD19/CD20/CD22) in an MHC-independent manner; CAR engagement triggers CD3ζ/co-stimulatory signaling, activating and expanding T cells to release cytotoxic mediators and kill antigen-positive tumor cells.
CAR-expressing T cells bind CD19 on target cells; CAR signaling activates cytotoxic T-cell effector functions, killing targets via perforin/granzyme release and death-receptor pathways (MHC-independent).
Autologous T cells genetically engineered to express chimeric antigen receptors for MHC-independent recognition of lymphoma antigens (e.g., CD19/CD20/CD22), leading to potent T-cell activation and cytolytic killing.
Autologous T cells are genetically engineered to express chimeric antigen receptors that recognize lymphoma antigens (e.g., CD19/CD20/CD22) in an MHC-independent manner; CAR engagement triggers CD3ζ/co-stimulatory signaling, activating and expanding T cells to release cytotoxic mediators and kill antigen-positive tumor cells.
CAR on engineered T cells binds CD20 on target cells, triggering T‑cell activation and cytolytic killing via perforin/granzyme (and Fas/FasL) in an MHC‑independent manner.
Autologous T cells genetically engineered to express chimeric antigen receptors for MHC-independent recognition of lymphoma antigens (e.g., CD19/CD20/CD22), leading to potent T-cell activation and cytolytic killing.
Autologous T cells are genetically engineered to express chimeric antigen receptors that recognize lymphoma antigens (e.g., CD19/CD20/CD22) in an MHC-independent manner; CAR engagement triggers CD3ζ/co-stimulatory signaling, activating and expanding T cells to release cytotoxic mediators and kill antigen-positive tumor cells.
CD22-targeted CAR T cells bind CD22 on tumor cells, activate via CD3ζ/co-stimulatory signaling, and kill through perforin/granzyme release and death-receptor (e.g., Fas/FasL) pathways.
Bispecific IgG antibodies that bind CD3 on T cells and a lymphoma-associated antigen to form an immune synapse, activating T cells to kill tumor cells.
Bispecific IgG antibodies that simultaneously bind CD3 on T cells and a lymphoma-associated antigen on tumor cells, physically bridging the cells to form an immune synapse. This triggers TCR/CD3 signaling, T-cell activation and cytokine release, leading to perforin/granzyme-mediated, MHC-independent lysis of the target tumor cell and serial killing.
The BiTE links CD3 on T cells to CD19 on target cells, forming an immune synapse that activates T cells to kill CD19+ cells via perforin/granzyme-mediated, MHC-independent cytolysis.
Bispecific IgG antibodies that bind CD3 on T cells and a lymphoma-associated antigen to form an immune synapse, activating T cells to kill tumor cells.
Bispecific IgG antibodies that simultaneously bind CD3 on T cells and a lymphoma-associated antigen on tumor cells, physically bridging the cells to form an immune synapse. This triggers TCR/CD3 signaling, T-cell activation and cytokine release, leading to perforin/granzyme-mediated, MHC-independent lysis of the target tumor cell and serial killing.
The bispecific antibody bridges CD3 on T cells to CD20 on target cells, forming an immune synapse that activates T cells to kill the CD20+ cells via perforin/granzyme-mediated cytolysis (MHC-independent).